Invivogen
Menu

Jurkat 4-1BB/4-1BBL assay

Product Unit size Cat. code Docs. Qty. Price

Jurkat-Lucia™ h4-1BB Cells

NF-κB-Luc Reporter T Lymphocytes expressing human 4-1BB

Show product

3-7 x 10e6 cells

jktl-41bb
+-
$1,693

Agonist screening assay for 4-1BB/4-1BBL axis

InvivoGen offers a cellular assay specifically designed for screening antibody-, Fc-fusion protein-, or small-molecule agonists of the 4-1BB/4-1BBL immune checkpoint (IC) axis:

  • Jurkat-Lucia™ h4-1BB: Reporter T cells

Principle of 4-1BB cellular assay
Principle of 4-1BB cellular assay
(click to enlarge)


4-1BB (also known as CD137 or TNFSF9) is a member of the TNFR (tumor necrosis factor receptor) superfamily. In humans, 4-1BB is expressed on a multitude of cells of the hematopoietic lineage. It is found on the surface of activated CD8+ and CD4+ T cells, including regulatory T cells (Tregs)  [1, 2]. The interaction of 4-1BB on T cells with its ligand, 4-1BBL (CD137L), on antigen-presenting cells (APCs), plays an important role in immune regulation. The 4-1BB/4-1BBL pair powerfully augments T-cell activation, proliferation, and survival and mediates memory T-cell generation [1, 2].

More details More details

 

Assay principle:

This assay relies on the monitored activation of Jurkat-Lucia™ h4-1BB cells which stably express cell surface 4-1BB, along with an NF-κB-inducible Lucia luciferase reporter gene.
In the presence of a potent 4-1BB agonist, such as Fc-h4-1BBL, the 4-1BB stimulation triggers NF-κB activation and Lucia production. Activation of the reporter T cells can be readily measured using QUANTI-Luc™ 4 Lucia/Gaussia detection reagent (see figures).

T-cell key features:

  • Stable human 4-1BB surface expression
  • Fully functional 4-1BB signaling pathway
  • NF-κB-inducible Lucia luciferase reporter activity

 

InvivoGen also offers Jurkat-Raji 4-1BB/4-1BBL (Bio-IC™), a cellular assay for screening antagonists of the 4-1BB/4-1BBL axis.

 

Read our review Read our review on Immune Checkpoint Blockade

Learn more about Immune Checkpoint Antibodies Learn more about Immune Checkpoint Antibodies.

 

References:

1. Bartkowiak, T. & Curran, M.A. 2015. 4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity. Front Oncol 5, 117.
2. Singh, R. et al., 2024. 4-1BB immunotherapy: advances and hurdles. Experimental & Molecular Medicine. 56(1):32-39.

Figures

4-1BB expression on Jurkat-Lucia™ h4-1BB cells
4-1BB expression on Jurkat-Lucia™ h4-1BB cells

Validation of human 4-1BB surface expression by Jurkat-Lucia™ h4-1BB cells. Jurkat (blue) and Jurkat-Lucia™ h4-1BB (red) cells were incubated with a PE‑conjugated Anti-h4-1BB mAb for 30 minutes. The binding affinity was measured using flow cytometry. Unstained cells are shown in grey.

Activation of Jurkat-Lucia™ h4-1BB cells
Activation of Jurkat-Lucia™ h4-1BB cells

Activation of Jurkat-Lucia™ h4-1BB cells. Jurkat-Lucia™ h4-1BB cells were incubated with increasing concentrations of recombinant human Fc-4-1BBL fusion protein for 24 hours. The NF-κB activation in Jurkat-Lucia™ h4-1BB cells was assessed by determining Lucia luciferase activity in the supernatant using QUANTI-Luc™ 4. Fold responses are shown as mean ± SEM.

Back to the top

Specifications

Growth medium: IMDM, 2 mM L-glutamine, 25 mM HEPES, 10% (v/v) heat-inactivated fetal bovine serum (FBS), 100 U/ml penicillin, 100 µg/ml streptomycin, 100 µg/ml Normocin™
Antibiotic resistance: Blasticidin and Zeocin®
Quality Control:

  • Human 4-1BB surface expression is confirmed by flow cytometry.
  • Reporter activity is validated following incubation with recombinant Fc-h4-1BBL protein
  • The stability for 20 passages following thawing is verified.
  • The cells are guaranteed mycoplasma-free.
     

These cells are covered by a Limited Use License (See Terms and Conditions).

Back to the top

Contents

  • 3-7 x 106 Jurkat-Lucia™ h4-1BB cells
  • 1 ml of Blasticidin (10 mg/ml)
  • 1 ml of Zeocin® (100 mg/ml)
  • 1 ml of Normocin™ (50 mg/ml). Normocin™ is a formulation of three antibiotics active against mycoplasmas, bacteria, and fungi.
  • 1 tube of QUANTI-Luc™ 4 Reagent, a Lucia luciferase detection reagent (sufficient to prepare 25 ml)

Shipped on dry ice Shipped on dry ice (Europe, USA, Canada)

Back to the top

FAQ Cell Lines

Visit our FAQ Any questions about our cell lines ? Visit our frequently asked questions page

Back to the top

Details

The 4-1BB/4-1BBL immune checkpoint

The 4-1BB/4-1BBL axis plays an important role in immune regulation and is considered an immune checkpoint (IC)

4-1BB (aka CD137 or TNFSF9) is a member of the TNFR (tumor necrosis factor receptor) superfamily. In humans, 4-1BB is expressed on a multitude of cells of the hematopoietic lineage. It is found on the surface of activated CD8+ and CD4+ T cells, including regulatory T cells (Tregs). Additionally, its expression can be induced on Natural Killer (NK) cells, B cells, monocytes, and  dendritic cells (DCs) upon activation [1,2].

4-1BBL (aka CD137L) is also a member of the TNFR family and is known as the sole ligand for 4-1BB. In humans, 4-1BBL is expressed in T cells, B cells, DCs and macrophages [1,2].

The interaction of 4-1BB on T cells with its ligand, 4-1BBL (CD137L), on antigen-presenting cells (APCs), triggers a TRAF1/TRAF2/NF‑κB‑dependent signaling which powerfully augments T-cell activation, proliferation, and survival [1]. This co-stimulatory axis also mediates the generation of memory T cells [1]

 

The 4-1BB/4-1BBL immune checkpoint in cancer

4-1BB expression in activated T cells has been an attractive target for cancer immunotherapy. Different strategies have been explored.
Two human agonistic monoclonal antibodies (mAbs) directed at 4-1BB, utomilumab (PF-05082566) and urelumab (BMS-663513), have entered phase I/II clinical trials. Whereas the IgG2 utomilumab is safe with relatively low efficacy, the IgG4 urelumab has a great antitumor efficacy but causes liver damage [2,3]. Utomilumab is being extensively tested in combination with IC inhibitory antibodies (e.g. Anti-CTLA-4 and Anti-PD-1) to treat different tumors, such as non-small cell lung cancer, kidney, head, and neck cancer [1,3]. Of note, agonistic 4-1BB mAbs may act on the depletion of Tregs through Fc-mediated effector functions [3]. A new generation of 4-1BB agonistic mAbs, other than utomilumab and urelumab, are being tested and are referenced in [2].
4-1BB-derived domains have been widely studied as costimulatory domains for genetically engineered T cells expressing chimeric antigen receptors (CART). The activation of the 4-1BB signaling in these CART cells promotes the formation of memory CART cells and long-term immune response against cancer cells [2,3].
4-1BB is expressed in various types of hematologic cancers and 4-1BBL in tumor cells, including carcinoma and colon cancers. However, the precise functions of 4-1BB/4-1BBL remain unclear in these malignancies [1, 2].

 

References:

1. Bartkowiak, T. & Curran, M.A. 2015. 4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity. Front Oncol 5, 117.
2. Singh, R. et al., 2024. 4-1BB immunotherapy: advances and hurdles. Experimental & Molecular Medicine. 56(1):32-39.
3. Mascarelli, D.E, et al., 2021. Boosting Antitumor Response by Costimulatory Strategies Driven to 4-1BB and OX40 T-cell Receptors. Front. Cell Dev. Biol. 10.3389/fcell.2021.692982.

Back to the top

Notification:  This product is for internal research use only. Additional rights may be available. Please visit InvivoGen’s Terms and Conditions.

Customer Service
& Technical Support
Shopping cart is empty